The second is evaluating the oncolytic MG1-MAGEA3 with Ad-MAGEA3 vaccine in combination with pembrolizumab (anti-PD-1 antibody) for patients with previously treated metastatic non-small cell lung cancer (NCT02879760). The gene discussed is MAGEA3; the disease is non-small cell lung carcinoma.